It belongs to a newer class of drugs sometimes called incretin or multi-agonist peptide therapies the same broad family as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)
"And they said: 'Look, we're pulling this medication
Our clientele comprises of pharmacies, patients, government and corporate hospitals, clinics, doctors, healthcare providers, and various other wholesalers
Slows Digestion: It can all keep the food in stomach longer, making that "full" feeling last
It raises prolactin
Methodological limitations of the available observational studies and randomized trials preclude definitive conclusions regarding the effects of GLP1RAs on the risk of various different malignancies